|Articles|May 6, 2003
Study shows moxifloxacin safe in treatment of bacterial conjunctivitis
Ft. Lauderdale-Results of an FDA Phase III study demonstrate that moxifloxacin ophthalmic solution 0.5% (Vigamox, Alcon) is a safe and effective treatment for bacterial conjunctivitis in adults and children as young as 1 month old, said Harold R. Katz, MD, speaking on behalf of the Moxifloxacin Conjunctivitis Study Group.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Study identifies corneal endothelial changes following mRNA COVID-19 vaccination
2
Moorfields study reveals sharp rise in glaucoma burden across the UK
3
Nanoscope’s gene therapy, MCO-010 receives Sakigake and Orphan Drug Designations in Japan
4
SpyGlass Pharma randomizes first patients in 2 phase 3 clinical trials of the BIM-IOL System
5










































